Sangamo's Fabry Gene Therapy May Be A STAAR In The Making
Looks To Challenge Enzyme Replacement Therapy Biweekly Infusions
The US biotech has presented interesting preliminary data from the first four patients treated in the Phase I/II STAAR study evaluating isaralgagene civaparvovec for Fabry.
